PharmaShots | Incisive News in 3 Shots

Subscribe Now

Innovent

Innovent and Ask Biopharma Receives China’s NMPA Approval for Limertinib to Treat Non-Small Cell Lung Cancer

Innovent and Ask Biopharma Receives China’s NMPA Approval for Limertinib to Treat Non-Small Cell Lung Cancer

January 17, 2025

Innovent’s IBI343 Secures the NMPA’s Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Innovent’s IBI343 Secures the NMPA’s Breakthrough Therapy Designation for Advanced Pancreatic Cancer

January 16, 2025

Innovent Reports the NMPA’s Approval of Dovbleron (Taletrectinib Adipate Capsule) for Treating ROS1-Positive NSCLC

Innovent Reports the NMPA’s Approval of Dovbleron (Taletrectinib Adipate Capsule) for Treating ROS1-Positive NSCLC

January 3, 2025

Innovent Reports the NMPA’s NDA Acceptance of Mazdutide to Treat Type 2 Diabetes

Innovent Reports the NMPA’s NDA Acceptance of Mazdutide to Treat Type 2 Diabetes

August 1, 2024

PharmaShots Weekly Snapshots (July 22 – July 26, 2024)

PharmaShots Weekly Snapshots (July 22 – July 26, 2024)

July 26, 2024

Innovent Reports Data from the P-III (DREAMS-1) Study of Mazdutide to Treat Type 2 Diabetes in Chinese Patients

Innovent Reports Data from the P-III (DREAMS-1) Study of Mazdutide to Treat Type 2 Diabetes in Chinese Patients

July 22, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us